Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The "KIF18A Targeting Therapies Market Trends, Clinical Trials, Technology Platforms & Future Outlook 2025" report has been added to ResearchAndMarkets.com's ...
The global oncology landscape is witnessing rapid progress in precision medicine, and one of the most lead nominees in emerging targets is Kinesin Family Member 18A (KIF18A). It is a mitotic motor ...
NEW YORK--(BUSINESS WIRE)--Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), today released preclinical data from the company’s ...
Company reports encouraging monotherapy expansion data in platinum-resistant ovarian cancer and initiates first combination study with standard-of-care chemotherapies in Q1 2026 Timothy Bowler, M.D., ...
Kuick Research Report highlights ongoing Clinical Development Technology platforms In Recent Research Study On KIF18A Therapies Delhi, July 12, 2025 (GLOBE NEWSWIRE) -- Global KIF18A Targeting ...
NEW YORK--(BUSINESS WIRE)--Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability (CIN), today announced new data from its lead program, a KIF18A inhibitor, ...
(MENAFN- GlobeNewsWire - Nasdaq) Explore the future of cancer treatment with the "Global KIF18A Targeting Therapies Market Trends, Clinical Trials, Technology Platforms & Future Outlook 2025" report.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results